1.4300 0.00 (0.00%)
After hours: 6:15PM EDT
|Bid||1.4200 x 3200|
|Ask||1.4400 x 40000|
|Day's Range||1.3800 - 1.4400|
|52 Week Range||1.2200 - 2.4000|
|Beta (5Y Monthly)||1.11|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug. 04, 2021 - Aug. 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that two poster presentations of new clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, will be made at the European Hematology Association (EHA) Annual Congress meeting to be held virtually from June 9 - 17. The abstracts for the posters are available on the EHA website at www.ehaweb.org. Both posters will be published on the EHA Virtual Congress platform on June 11, 2021.
Good day and thank you for standing by and welcome to the Q1 2021 Geron earnings conference call. Welcome to this conference call to discuss Geron's first-quarter 2021 financial results and recent company events.
Geron (GERN) delivered earnings and revenue surprises of -12.50% and 82.67%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?